risedronic acid has been researched along with Cystic Fibrosis of Pancreas in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haworth, CS | 1 |
| Sharples, L | 1 |
| Hughes, V | 1 |
| Elkin, SL | 1 |
| Hodson, ME | 1 |
| Conway, SP | 1 |
| Etherington, C | 1 |
| Elborn, JS | 1 |
| Rendall, J | 1 |
| Wheaton, E | 1 |
| Kadri, E | 1 |
| Elliott, J | 1 |
| Barker, HC | 1 |
| Bearcroft, PW | 1 |
| Hlaing, T | 1 |
| Compston, JE | 1 |
1 trial available for risedronic acid and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Cystic Fibrosis; Drug Administration Schedule | 2011 |